- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00001437
Trial of Pentoxifylline in Patients With Functional Disability Caused by Radiation-Induced Advanced Regional Fibrosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients with late fibrovascular sequelae of radiation or of combined radiation and surgery, with quantifiable symptomatology or disability, will be eligible for this trial. This protocol is designed as an open label one arm study. (A placebo controlled randomized trial was approved by the IRB but after extensive negotiation, drug and placebo in slow release formulation will not be provided by the manufacturer). Up to fifty patients will be recruited. After initial assessment of their condition by specified clinical and laboratory parameters, each of the patients will be treated for 8 weeks at the standard pentoxifylline dose (400 mg po TID). Objective and subjective response parameters will be re-assessed at the end of the treatment and 8 weeks later for possible decay of response.
In addition to symptomatic objective and subjective response, blood and urine will be collected for TNF, TGF-beta, and FGF. Cutaneous blood flow and collagen subtyping will be performed on a subset of patients using Laser Doppler, functional MRI techniques and subcutaneous tissue biopsies. We will examine for correlation between clinical response and these biological responses.
Study Type
Enrollment
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Cancer Institute (NCI)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
POPULATION CHARACTERISTICS:
Regional advanced postradiation fibrosis of the neck, chest wall, pelvis, or extremities causing measurable impairment of specific function, i.e.: Decreased range of motion, Weakness, Sensory deficit, Pain requiring narcotics, Significantly altered activities of daily living.
None of these conditions present either before or during radiotherapy or attributed to surgery or chemotherapy.
Patients with prostate cancer allowed if prostate-specific antigen (PSA) is less than 4.0 ng/mL and the last 3 PSA values were stable or decreasing. Abnormal bone scan or film acceptable if consistent with degenerative disease.
No recurrent or metastatic cancer.
No concurrent second cancer.
PRIOR/CONCURRENT THERAPY: At least 3 months since pentoxifylline.
PATIENT CHARACTERISTICS:
Age: 18 and over.
Performance status: Karnofsky 70%-100% (unrelated to postradiation fibrosis).
CARDIOVASCULAR:
No symptomatic coronary artery disease with frequent anginal episodes necessitating any of the following during past 6 months: Coronary artery bypass, Angioplasty, Pacemaker placement, Thrombolytic treatment.
No chronic cardiac failure with persistent hemodynamic abnormality and ejection fraction less than 40%.
No coagulation, platelet, or vascular disorder that threatens to cause bleeding.
OTHER:
No intolerance to pentoxifylline or other xanthines (e.g., caffeine, theophylline, theobromine).
No seizure disorder.
No peptic ulcer disease.
Willing to undergo serial evaluations (excluding biopsies, laser Doppler, MRI) by NCI rehabilitation specialist for documentation and grading of functional disability.
No pregnant or nursing women.
Adequate contraception encouraged in fertile women.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Wounds and Injuries
- Fibrosis
- Radiation Injuries
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Enzyme Inhibitors
- Platelet Aggregation Inhibitors
- Protective Agents
- Antioxidants
- Phosphodiesterase Inhibitors
- Free Radical Scavengers
- Radiation-Protective Agents
- Pentoxifylline
Other Study ID Numbers
- 950138
- 95-C-0138
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fibrosis
-
San Gerardo HospitalCompletedIdiopathic Pulmonary Fibrosis | Cardiac Fibrosis | Arterial FibrosisItaly
-
Peking Union Medical College HospitalRecruitingIdiopathic Retroperitoneal FibrosisChina
-
St. Antonius HospitalZonMw: The Netherlands Organisation for Health Research and Development; Boeringer...RecruitingPulmonary Fibrosis Idiopathic FamilialNetherlands
-
Assistance Publique - Hôpitaux de ParisRecruitingIdiopathic Retroperitoneal FibrosisFrance
-
Peking Union Medical College HospitalRecruitingIdiopathic Retroperitoneal FibrosisChina
-
University of ParmaUnknownIdiopathic Retroperitoneal Fibrosis | Perianeurysmal Retroperitoneal Fibrosis | Chronic PeriaortitisItaly
-
Peking Union Medical College HospitalRecruiting
-
Peking Union Medical College HospitalRecruiting
-
Hospital de Clinicas de Porto AlegreUnknownCystic Fibrosis | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in Children | Cystic Fibrosis With ExacerbationBrazil
-
University Hospital, GrenobleNot yet recruiting
Clinical Trials on pentoxifylline
-
Hospital Universitario de CanariasUnknown
-
Beijing Tiantan HospitalCSPC Ouyi Pharmaceutical Co., Ltd.Not yet recruitingCerebral Small Vessel DiseasesChina
-
Institute of Liver and Biliary Sciences, IndiaUnknown
-
Hospital Universitario de CanariasInstituto Médico Tinerfeño IMETISAUnknown
-
Assistance Publique - Hôpitaux de ParisMerck Sharp & Dohme LLCCompletedBenign Prostatic Hyperplasia (BPH) Requiring Surgical ResectionFrance
-
Alexandria UniversityNot yet recruiting
-
National Taiwan University HospitalCompletedPrimary GlomerulonephritisTaiwan
-
University of MichiganCompletedAcute Kidney FailureUnited States
-
University of Alabama at BirminghamTerminated